Nasdaq approved Canary Capital’s Staked INJ ETF listing on November 4, 2026, giving Injective’s INJ token a route into the regulated US securities market with potential staking rewards. The Injective ETF approval marks an institutional milestone, but it is not the start of trading. Separately, INJ recovered to around $7.64, above a closely followed breakout level.